Peptides
PNC-27
Also called PNC27
PNC-27 attracts attention because researchers found it could damage cancer-cell membranes in laboratory experiments. People facing difficult cancer decisions naturally want to know whether that can become a treatment. The reviewed work does not show that PNC-27 improves survival, shrinks a person’s cancer or safely replaces an established therapy.
Dosage & duration
Cancer-treatment dose and course
Clinical treatment context
Published example · product-specific- Dose
- No established treatment amount
- How often
- No validated patient schedule
- How long
- No established course
The cited experiments do not define a human dose. We do not turn commercial protocol sheets into an oncology regimen.
Discuss an experimental product with the oncology team before changing or delaying treatment; include its exact name and source.
How it fits together
What would make PNC-27 a useful cancer treatment?
People want tumor control, symptom relief or more time. The cited PNC-27 research does not establish those outcomes in patients.
-
A laboratory signal
The cited experiments studied cancer cells, including cells originally taken from humans.
-
A usable treatment
Those findings do not show that treatment reaches a tumor safely in a person.
-
A meaningful benefit
Improved survival, symptoms or tumor control remain unestablished by these studies.
Why is PNC-27 called an anticancer peptide?
Laboratory work examined a way to disrupt cancer-cell membranes. This is a genuine research idea, but “anticancer” in a paper title does not mean a product has been shown to treat someone’s cancer.
Does “human pancreatic cancer” mean it worked in patients?
Not in the cited experiments: it refers to the origin of the cells. Cells in a dish do not reproduce delivery through the body, tumor access, effects on healthy organs or interactions with cancer treatment.
What about the dosing sheets online?
Commercial sheets publish amounts without supplying the clinical dose-finding and outcome evidence needed to support them. A vial size, an animal experiment or cell concentration cannot establish a safe cancer course.
A useful next question
Ask the treating team whether there is a registered clinical study that fits the cancer type and treatment history. That is more informative than a generic success story. Keep any experimental product on the medication list rather than assuming a peptide cannot interact with care.
Model details: PNC-27 · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 0.96 h is a scenario assumption; cell lysis onset and in-vitro exposure duration are not elimination.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.96 hours
- Absorption half-life assumed
- 0.24 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Cell-culture concentrations cannot be used as injected blood Cmax.
- Do not substitute PNC-28 or a different delivery conjugate.
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
Legacy 0.96 h is a scenario assumption; cell lysis onset and in-vitro exposure duration are not elimination.
pnc-27-relative-timing-2026-10 · version 1
Common questions
Has PNC-27 been proven to treat pancreatic cancer?
The cited pancreatic-cancer work studied cells. It does not establish tumor response or survival benefit in patients.
Why not show an online cancer protocol?
An unvalidated amount can look like a treatment recommendation. The available commercial sheet does not establish a patient dose or course, and cancer treatment should not be delayed on that basis.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Why the interest
- Selective effects in a laboratory are the attraction, not a demonstrated cure.
- Meaning of human cells
- A cell line from a person is not a trial in patients.
- Clinical dose
- Commercial amounts do not establish an effective or safe cancer regimen.
- 1. PNC-27 membrane-pore study, 2022
Original abstract inspected: cell/structural mechanism; not treated cancer patients.
- 2. PNC-27 pancreatic-cancer cell study, 2024
Original study abstract inspected: human cancer cells in laboratory experiments, not a clinical treatment trial.
- 3. Genoracle PNC-27 doctor sheet
Commercial schedule found in live search. Does not supply dose-finding or cancer-outcome evidence; no numeric treatment protocol adopted.
- 4. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
Legacy 0.96 h is a scenario assumption; cell lysis onset and in-vitro exposure duration are not elimination.
Related compounds and examples
Related compounds
Thymosin Alpha-1
Thymosin Alpha-1: immune-support claims, Zadaxin doses and why the illness being treated matters.
LL-37 (Cathelicidin)
LL-37 for immune, gut and wound-healing questions: what people seek, reported injection amounts and what topical human trials actually found.
KPV
KPV for gut and skin concerns: oral versus injected products, reported dose context and realistic expectations for inflammation claims.